Compare SUVEN LIFE with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES AUROBINDO PHARMA SUVEN LIFESCIENCES/
AUROBINDO PHARMA
 
P/E (TTM) x 19.2 14.5 132.1% View Chart
P/BV x 3.9 3.2 123.2% View Chart
Dividend Yield % 0.5 0.4 136.6%  

Financials

 SUVEN LIFESCIENCES   AUROBINDO PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
AUROBINDO PHARMA
Mar-18
SUVEN LIFESCIENCES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs338809 41.7%   
Low Rs169504 33.6%   
Sales per share (Unadj.) Rs52.1281.1 18.5%  
Earnings per share (Unadj.) Rs6.841.4 16.5%  
Cash flow per share (Unadj.) Rs8.650.9 16.8%  
Dividends per share (Unadj.) Rs1.502.50 60.0%  
Dividend yield (eoy) %0.60.4 155.4%  
Book value per share (Unadj.) Rs65.3199.4 32.7%  
Shares outstanding (eoy) m127.28585.88 21.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.3 208.2%   
Avg P/E ratio x37.115.9 233.8%  
P/CF ratio (eoy) x29.612.9 229.3%  
Price / Book Value ratio x3.93.3 117.9%  
Dividend payout %22.06.0 363.3%   
Avg Mkt Cap Rs m32,272384,630 8.4%   
No. of employees `0001.117.3 6.2%   
Total wages/salary Rs m66121,308 3.1%   
Avg. sales/employee Rs Th6,132.29,500.7 64.5%   
Avg. wages/employee Rs Th611.11,229.4 49.7%   
Avg. net profit/employee Rs Th803.51,397.9 57.5%   
INCOME DATA
Net Sales Rs m6,635164,666 4.0%  
Other income Rs m2421,020 23.8%   
Total revenues Rs m6,877165,686 4.2%   
Gross profit Rs m1,60437,718 4.3%  
Depreciation Rs m2215,580 4.0%   
Interest Rs m38777 4.9%   
Profit before tax Rs m1,58732,380 4.9%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7188,183 8.8%   
Profit after tax Rs m86924,229 3.6%  
Gross profit margin %24.222.9 105.6%  
Effective tax rate %45.225.3 179.0%   
Net profit margin %13.114.7 89.1%  
BALANCE SHEET DATA
Current assets Rs m6,232121,878 5.1%   
Current liabilities Rs m1,49086,806 1.7%   
Net working cap to sales %71.521.3 335.6%  
Current ratio x4.21.4 297.9%  
Inventory Days Days86130 66.6%  
Debtors Days Days8368 120.8%  
Net fixed assets Rs m4,04381,037 5.0%   
Share capital Rs m127586 21.7%   
"Free" reserves Rs m8,183116,218 7.0%   
Net worth Rs m8,310116,804 7.1%   
Long term debt Rs m184,512 0.4%   
Total assets Rs m10,389211,052 4.9%  
Interest coverage x43.142.7 101.0%   
Debt to equity ratio x00 5.5%  
Sales to assets ratio x0.60.8 81.9%   
Return on assets %8.711.8 73.7%  
Return on equity %10.520.7 50.4%  
Return on capital %19.527.4 71.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62280,727 7.0%   
Fx outflow Rs m1,79934,700 5.2%   
Net fx Rs m3,82246,027 8.3%   
CASH FLOW
From Operations Rs m35619,548 1.8%  
From Investments Rs m-279-19,570 1.4%  
From Financial Activity Rs m-2258,642 -2.6%  
Net Cashflow Rs m-1488,922 -1.7%  

Share Holding

Indian Promoters % 63.4 54.1 117.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.0 -  
FIIs % 0.0 27.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.2 357.8%  
Shareholders   37,287 69,601 53.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ALEMBIC LTD  ORCHID PHARMA LTD  SANOFI INDIA  FDC LTD.  NOVARTIS  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 13, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS